Catalent’s Strategic Pivot Under Novo Holdings

Catalent US1488061029

The strategic importance of contract manufacturer Catalent to the global pharmaceutical supply chain has come into sharp relief more than a year after its acquisition by Novo Holdings. Now operating as a private entity, its capacity to produce high-demand therapies like Wegovy is a cornerstone of its parent company's success. Industry observers are closely monitoring how effectively the newly configured production network is performing.

A pivotal moment arrived in December 2024 with the completion of a $16.5 billion acquisition by Novo Holdings. As part of this transaction, three specialized manufacturing facilities located in Italy, Belgium, and the United States were transferred directly to Novo Nordisk. This move was designed to create a permanent solution for production bottlenecks affecting GLP-1 medications.

The critical nature of these assets is underscored by the recent U.S. launch of an oral formulation of Wegovy. Following FDA approval in late 2025, Novo Nordisk commenced distribution in January 2026. The ability to meet the substantial demand for this new dosage form relies heavily on the operational efficiency of the former Catalent sites.

Advancing Cell Therapy Capabilities

Alongside its integration into the Novo corporate structure, Catalent continues to pursue its own business development. In mid-January 2026, the company entered into a non-exclusive licensing agreement with SmartCella. The partnership aims to supply Good Manufacturing Practice (GMP)-compliant induced pluripotent stem cells (iPSCs).

This collaboration signals Catalent's ongoing central role in supporting the development of advanced cell therapies. It remains a key partner for biotechnology firms that depend on standardized starting materials for their research pipelines.

Operational Metrics Take Center Stage

With Catalent no longer publicly traded, the focus for analysts has shifted to purely operational performance indicators. The coming months will reveal how seamlessly the integrated sites are functioning within Novo Nordisk's broader network. Supply chain reliability for GLP-1 products is viewed as the primary benchmark for success.

Market experts are also monitoring the pipeline of Catalent's external clients. The commercial performance of drugs it continues to manufacture for third parties will offer insights into the long-term health of its service business. Potential synergy announcements or further investment plans from Novo Holdings may soon provide additional clarity on the company's strategic direction under its new ownership.

• Key Transaction: Acquired by Novo Holdings for $16.5 billion (December 2024).
• Asset Transfer: Three production sites moved to Novo Nordisk for capacity expansion.
• Product Launch: Oral Wegovy variant launched in the U.S. (January 2026).
• Research Partnership: New agreement with SmartCella in stem cell therapy (January 2026).